As on 28-Mar-2024 16:18 EDT
$28.82
$29.99
$31.00
$29.36
95,945
$4.00 - 31.00
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Jasper Therapeutics (JSPR)
| 272.12 | 39.61 | 375.85 | 57.85 | -33.27 | -- | -- |
S&P BSE Sensex
| 1.95 | 0.76 | 2.24 | 27.75 | 14.54 | 14.07 | 12.73 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
2023
|
2022
|
|
---|---|---|
Jasper Therapeutics (JSPR)
| 63.35 | -93.85 |
S&P Small-Cap 600
| 13.89 | -17.42 |
S&P BSE Sensex
| 18.74 | 4.44 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Jasper Therapeutics Inc. (JSPR) stood at $ 95 Mln as on 31-Dec-23
The share price of Jasper Therapeutics Inc. (JSPR) is $29.36 (NASDAQ) as of 28-Mar-2024 16:18 EDT. Jasper Therapeutics Inc. (JSPR) has given a return of -33.27% in the last 3 years.
Jasper Therapeutics Inc. (JSPR) has a market capitalisation of $ 420 Mln as on 28-Mar-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Jasper Therapeutics Inc. (JSPR) is 5.32 times as on 28-Mar-2024, a 0.61% premium to its peers’ median range of 3.30 times.
Since, TTM earnings of Jasper Therapeutics Inc. (JSPR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jasper Therapeutics Inc. (JSPR) and enter the required number of quantities and click on buy to purchase the shares of Jasper Therapeutics Inc. (JSPR).
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California. Address: 2200 Bridge Pkwy, Redwood City, CA, United States, 94065
The CEO & director of Mr. Ronald A. Martell. is Jasper Therapeutics Inc. (JSPR), and CFO & Sr. VP is Dr. Judith Anne Shizuru M.D., Ph.D..
The promoters of Jasper Therapeutics Inc. (JSPR) have pledged 0% of the total equity as on Sep-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
872
|
|
807
|
|
778
|
|
768
|
Jasper Therapeutics Inc. (JSPR) | Ratios |
---|---|
Return on equity(%)
|
-112.67
|
Return on capital employed(%)
|
-106.67
|
Debt-to-equity ratio
|
0.04
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Jasper Therapeutics Inc. (JSPR) was $-30 Mln.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases,... such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California. Address: 2200 Bridge Pkwy, Redwood City, CA, United States, 94065 Read more